Rakovina Therapeutics IncOTC Pink - Current Information:RKVTFView on Canadian Exchange
- LAST PRICE0.0800
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close--- / 0.0800
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
Nov 20, 2024
Rakovina Therapeutics Announces Upcoming Poster Presentation at the 29th Annual Society for Neuro-Oncology Meeting in Houston, Texas, from 4:30PM ET on Wednesday Nov 20, 2024 by Dow Jones
4:30PM ET on Wednesday Nov 20, 2024 by Dow Jones
Oct 25, 2024
Oct 23, 2024
Rakovina Therapeutics Announces Initial Drug Candidates from Deep Docking AI Molecule Discovery Platform, from 7:30AM ET on Wednesday Oct 23, 2024 by Dow Jones
7:30AM ET on Wednesday Oct 23, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Rakovina Therapeutics Inc | 5.0M | --- | --- |
Company Information
Rakovina Therapeutics Inc. is a Canada-based biopharmaceutical research company. The Company is focused on the development of new cancer treatments based on novel deoxyribonucleic acid (DNA)-damage response technologies. Its drug development pipeline includes kt-2000AI and kt-3000 series. It is engaged in employing the proprietary Deep Docking AI Platform to rapidly screen billions of potential drug candidates against PARP (kt-2000AI) and other novel DDR targets to generate drug candidates that can be advanced to human trials or developed in collaboration with pharmaceutical partners. Its kt-3000 series represents a novel class of bi-functional small-molecule drug candidates that has been designed to combine inhibition of both poly (ADP)-ribose polymerase (PARP) and histone deacetylase (HDAC) in a single molecule. This novel approach has the potential to overcome treatment resistance and provide clinical benefit to cancer patients.
Contact Information
- Headquarters
- 105 - 1008 Beach AvenueVancouver, BC, Canada V6E 1T7
- Phone
- 604-619-0225
- Fax
- 604-980-6264
Executives
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $5.0M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 90.3M |
Rakovina Therapeutics Inc does not pay a dividend. | |
Beta | -0.10 |
EPS | $-0.04 |
Book Value | $0.05 |
P/E Ratio | --- |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
